Age-Related Macular Degeneration

Aetna covers treatment of neovascular (wet) age‑related macular degeneration with specified anti‑VEGF agents (aflibercept, bevacizumab, pegaptanib, ranibizumab) and verteporfin photodynamic therapy when provided according to the applicable Aetna clinical policy bulletins. Aetna considers numerous diagnostics, genetic/polymorphism testing, complement inhibitors, gene/stem‑cell therapies, many pharmacologic/surgical approaches and listed CPT/HCPCS/drug codes experimental/investigational and not covered.

"No explicit Medicare/coverage-specific documentation requirements are stated in this document."

Sign up to see full coverage criteria, indications, and limitations.